Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

NT219

Small molecule · Inhibitor of insulin receptor substrate 1 (IRS1), insulin receptor substrate 2 (IRS2) and signal transducer and activator of transcription 3 (STAT3)

Phase 1/2 Most advanced trial
1 Registered trials

What is NT219?

NT219 is a small molecule that binds and inhibits IRS1, IRS2 and STAT3, preventing STAT3 nuclear translocation and IRS-mediated survival signaling in tumor cells. It is being studied in head and neck squamous cell carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
insulin receptor substrate 1 (IRS1), insulin receptor substrate 2 (IRS2), signal transducer and activator of transcription 3 (STAT3)
Mechanism
Inhibitor of insulin receptor substrate 1 (IRS1), insulin receptor substrate 2 (IRS2) and signal transducer and activator of transcription 3 (STAT3)
Pathways
IRS1/2-mediated signaling, STAT3 nuclear translocation and oncogene expression, apoptosis
Therapy area
Oncology
In trials of
PPBT
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
K1WT1A1UP5

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06919666 Phase 1/2 Head and Neck Cancer Active not recruiting PPBT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Head and Neck CancerHead and Neck Squamous Cell Carcinoma

Other drugs acting on IRS1 / IRS2 / STAT3

Sources

Updated Oct 25, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.